Enabling stop codon read-through  translation in bacteria as a probe  for amyloid aggregation by Molina-García, Laura & Giraldo, R.
1Scientific REPORts | 7: 11908  | DOI:10.1038/s41598-017-12174-0
www.nature.com/scientificreports
Enabling stop codon read-through 
translation in bacteria as a probe 
for amyloid aggregation
Laura Molina-García1,2 & Rafael Giraldo1
Amyloid aggregation of the eukaryotic translation terminator eRF3/Sup35p, the [PSI+] prion, 
empowers yeast ribosomes to read-through UGA stop codons. No similar functional prion, skipping a 
stop codon, has been found in Escherichia coli, a fact possibly due to the efficient back-up systems found 
in bacteria to rescue non-stop complexes. Here we report that engineering hydrophobic amyloidogenic 
repeats from a synthetic bacterial prion-like protein (RepA-WH1) into the E. coli releasing factor RF1 
promotes its aggregation and enables ribosomes to continue with translation through a premature 
UAG stop codon located in a β-galactosidase reporter. To our knowledge, intended aggregation of a 
termination factor is a way to overcome the bacterial translation quality checkpoint that had not been 
reported so far. We also show the feasibility of using the amyloidogenic RF1 chimeras as a reliable, 
rapid and cost-effective system to screen for molecules inhibiting intracellular protein amyloidogenesis 
in vivo, by testing the effect on the chimeras of natural polyphenols with known anti-amyloidogenic 
properties. Resveratrol exhibits a clear amyloid-solubilizing effect in this assay, showing no toxicity to 
bacteria or interference with the enzymatic activity of β-galactosidase.
The yeast prion [PSI+], which is the amyloid-aggregated form of the Sup35p translation termination/ribosome 
releasing factor three (eRF3), expands the diversity of the proteome by reading through the UGA stop codon 
and is a widely studied basic model for amyloidogenesis and epigenetics1. In bacteria translation termination 
is dependent on the releasing factor 1 (RF1), which recognises the UAG and UAA stop codons, and releasing 
factor 2 (RF2) that recognizes UAA and UGA. Both factors are released from the ribosomal A site by the action 
of a GTPase (RF3, a Sup35p orthologue)2,3. The elucidation of bacterial ribosome structures in their different 
functional states has facilitated the characterization of the mechanism of action of RF1 and RF24,5. These proteins 
are structural analogues of tRNAs that occupy the ribosomal A site over the termination codons, thereby plac-
ing amino acid side-chains to recognise the stop triplet, while projecting their respective N-terminal domains 
towards the exterior of the ribosome (Fig. 1a). Under conditions wherein the availability of RF1/RF2 is drastically 
reduced, when a stop codon is reached by the ribosome there is a pause in the translation and an anti-terminator 
aminoacylated tRNA inefficiently replaces RF1/2, thereby allowing for stop codon read-through in a discrete 
fraction of the pause events. The strict quality control exerted in E. coli6–8, either on the stability of incompletely 
translated messengers or on partially synthesised proteins following a stop or a pause during elongation, may be 
a reason why translation termination in bacteria has not yet been exploited for biotechnological purposes, such 
as drug screening.
Model systems of protein amyloidoses, spanning from Alzheimer’s, Parkinson’s and prion neurodegenerative 
diseases to diabetes, have been successfully developed on the basis of eukaryotic organisms such as yeast, worms, 
flies, mice and, more recently, human stem cells9. Beyond their contribution to our understanding of amyloidoses, 
such models have enabled screening for anti-amyloidogenic compounds10. However, issues including the time 
needed to get a measurable signal or phenotype and, in the case of animal models, the requirement of fulfill-
ing the two first of ‘the three Rs’ of Bioethics (the Replacement of animals and the Reduction in the number of 
them used)11, still press in favour of developing alternative screening platforms for biotechnological applications. 
Bacteria such as Escherichia coli, in spite of their ease and robustness of handling and the subsequent savings in 
cost and time, have been less used as proxies to amyloid diseases due to the evolutionary distance between prokar-
yotes and humans. There are a few exceptions, including extracellularly secreted bacterial amyloids, such as curli/
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CsgA12 and related amyloids, which scaffold biofilms and have been recently engineered to survey the amyloido-
genic potential of any secreted protein and to test the anti-amyloidogenic activity of natural compounds13. More 
recently, bacteria have been also engineered to develop an assay in which the aggregation of β-lactamase in the 
periplasm, and thus the resistance levels against β-lactam antibiotics, is modulated by the aggregative potential 
of peptides fused to the enzyme14. Regarding intracellular amyloids, straight fusions of GFP to amyloidogenic 
peptides have been used to get a read-out of aggregation correlated with a loss in fluorescence emission15.
In this work, we have challenged the view that, upon ribosome stalling on a stop codon, the trans-translation 
checkpoint cannot be easily overcome in bacteria6–8, by exploring the feasibility of modifying one of the releasing 
factors in E. coli (RF1) to become inactivated through amyloid aggregation. Thus, we have generated chime-
ras between RF1 and a hydrophobic peptide of bacterial origin: the amyloidogenic stretch in the RepA-WH1 
prionoid16. This prion-like protein was chosen as a proof of concept because it is the prototype of a bacte-
rial intracellular amyloidosis, relevant as a model for human amyloid diseases since it elicits in E. coli a ver-
tically (mother-to-daughter cells) transmissible amyloid proteinopathy17, propagating as alternative Hsp70 
chaperone-modulated conformational strains18. Furthermore, RepA-WH1 exhibits cross-seeding both in vitro 
and in vivo17,19, and shares pathways of toxicity with mitochondrial routes of amyloid disease (i.e., membrane 
targeting and ROS generation)20,21. The amyloidogenic, hydrophobic sequence in RepA-WH1 was recently found 
to functionally replace the polar repeated sequences that enable the yeast prion [PSI+] to aggregate22. As a proof 
of concept, we also show that these chimeras constitute in bacteria a useful intracellular screening system for 
anti-amyloidogenic compounds, as described for analogous reporters built on [PSI+] in yeast23,24.
Results and Discussion
Design of chimeras between amyloidogenic sequences and the E. coli releasing factor RF1. In 
yeast Sup35p, polar Q/N-rich sequences govern the aggregation of the protein as the [PSI+] prion, which enables 
stop-codon read-through by ribosomes1,23,24. We have recently shown that 2-4 repeats of a hydrophobic and amy-
loidogenic sequence (LVLCAVSLI) from the bacterial prion-like protein RepA-WH125, can functionally replace 
in yeast the polar Q/N oligopeptide repeats in [PSI+] resulting in a new synthetic prion, [REP-PSI+]22. To explore 
the possibility of generating an analogous synthetic prion in bacteria, thus enabling an epigenetic control on 
bacterial translation termination, we have now engineered the same amyloidogenic repeats of the RepA-WH1 
sequence, in short WH1(R0-4), at the N-terminus of the E. coli RF1.
A strain carrying a thermosensitive allele of prfA26, the gene encoding RF1, in which we had deleted the lacZ 
gene (MRA8-∆lacZ, prfAts) was used as host. In this strain, RF1ts allows a normal termination of translation at 
UAG codons at 30 °C, whereas at 42 °C RF1ts is disabled and thus translation termination is impaired, depending 
on complementation by a functional prfA gene. The expression of the WH1(R0-4)-RF1 chimeras in conditions 
promoting amyloidogenic aggregation (42 °C) would make translation termination defective, thus leading to 
read-through stop codons (Fig. 1b).
A first plasmid construct series allowed for IPTG-induced expression of the His6-tagged WH1(R0-4) repeats 
fused to RF1, enabling complementation of the host RF1ts (Fig. 2a). Two compatible reporter plasmids allowed 
for arabinose induction of lacZ by carrying either a UAA stop codon at its natural terminus (lacZ-WT), or an 
additional premature amber (UAG) mutation (lacZ-amber) generating a truncated and inactive enzyme (Fig. 2b). 
Such lacZ-amber reporter gives a blue or white coloration to bacteria depending, respectively, on the synthesis, or 
not, of the full length β-galactosidase enzyme (Fig. 2c).
Figure 1. Amyloidogenic peptide tagging at the N-terminus of RF1 enables aggregation-dependent stop 
codons reading-through by E. coli ribosomes. (a) A bacterial ribosome assembled around a stop codon, showing 
the tRNAs bound at the P (peptidyl) and E (exit) sites and a RF1 molecule bound at the A (amino-acyl) site. 
The solvent-accessible N-terminus of RF1, where the WH1(Rn) peptides were attached is indicated. Structure 
rendered with PyMOL v.1.4 (https://www.pymol.org) on the PDB file 4v63. (b) A cartoon of the functional 
expansion in translation termination implemented in this report: bacterial ribosomes recognize or read-
through amber stop codons depending on the solubility (left) or aggregation (right) of peptide-tagged RF1 
(yellow).
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Aggregation of WH1(R2-4)-RF1 chimeras enables stop codon read-through in E. coli. In 
cells expressing WH1(R0-4)-RF1 and carrying the lacZ-WT reporter, when grown at the permissive tempera-
ture (30 °C) on agar plates carrying the chromogenic substrate X-Gal, the characteristic blue-green colour was 
observed (Fig. 3a, top-left). In contrast, this blue-green colour was not observed in bacteria grown in the same 
conditions but carrying the lacZ-amber reporter, indicating an efficient translational termination, as expected 
(Fig. 3a, bottom-left). At the non-permissive temperature (42 °C), there was no apparent change, neither in colour 
nor in growth, in cells carrying the lacZ-WT reporter (Fig. 3a, top-right), due to the end of translation determined 
by RF2 at the terminal UAA stop codon. However, in the case of the lacZ-amber reporter only those bacteria 
bearing RF1 chimeras with at least two amyloidogenic repeats, WH1(R2-4)-RF1, displayed a blue-green colour at 
42 °C (Fig. 3a, bottom-right). This pointed to the efficient read-through by the ribosomes of the premature amber 
codon in the high copy-number lacZ-amber mRNA, as a consequence of a loss of function in the WH1(R2-
4)-RF1 chimeras. To test the ability of the engineered translation termination device to generate a signal amenable 
to high-throughput screening, bacteria were also grown in minimal liquid medium in multi-well plates. Colour 
Figure 2. Design of the WH1(R0-4)-RF1 chimeras and the reporter lacZ-WT/amber plasmids. (a) The 
plasmid-borne fusions of the RepA-WH1 amyloidogenic peptides to E. coli RF1 (prfA gene). The control 
WH1(R0)-RF1 fusion (top) encodes at the N-terminus a His6-tag (green), two unique restriction sites and a 
flexible long linker (black) just before RF1 (red). The WH1(Rn)-RF1 chimeras accommodate the hydrophobic 
RepA-WH1 peptide repeats (blue; encircled: the hyper-amyloidogenic A31V mutation)22. Triplets encoding 
the Gly residues required to build the turn between the amyloidogenic repeats are also highlighted (orange). 
Just the single peptide repeat (R1, middle) and the final four repeats (R4, bottom) are displayed. (b) Arabinose-
promoted expression (pBAD) cassette (left) with a wild-type lacZ reporter (blue) (top) or a mutated lacZ-amber 
variant carrying a premature UAG stop codon (bottom). (c) Functional assays in an E. coli MRA8-∆lacZ, prfAts 
background. Complementation by the lacZ-WT construct leads to blue coloured bacteria (left). On the contrary, 
the expression of the lacZ-amber variant was unable to complement, due to the premature end of lacZ-amber 
translation (right). Experiment carried out at 30 °C because, in the absence of the WH1(Rn)-RF1 chimeras, 
translation termination is dependent on the host RF1ts.
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phenotypes similar to those observed for the agar plates were obtained (Fig. 3b). Accordingly, β-galactosidase 
assays in vitro showed that at 42 °C the enzymatic activity for WH1(R2-4)-RF1 in lacZ-amber backgrounds, nor-
malized to the corresponding value for the same chimeras in combination with the lacZ-WT reporter, increased 
progressively with the number of amyloidogenic tandem repeats, peaking at 3 h post-induction (Fig. 3c). With the 
lacZ-WT reporter, similar levels of β-galactosidase activity were achieved for all the chimeras, with no significant 
difference between the number of repeats in WH1(R2-4)-RF1 (Fig. 3c, inset).
Altogether, these results indicate that the aggregation of RFs can enhance stop codon read-through, and con-
stitute a proof of concept on the feasibility of engineering a bacterial sensor for the amyloid aggregation of peptide 
stretches based on the same principle governing the [PSI+] prion in yeast.
Aggregation of WH1(R2-4)-RF1 chimeras is a suitable target for screening of anti-amyloidogenic 
compounds. To determine the feasibility of using the bacterial sensor in screens for anti-amyloidogenic com-
pounds, we tested a number of distinct polyphenolic molecules known to have such activity (Fig. 4)10. We found 
that, at 42 °C and with the lacZ-amber reporter, the sensor including the WH1(R2-4)-RF1 chimeras efficiently 
monitored the anti-amyloidogenic activity of resveratrol and, to a lesser extent, of epigallocathequin-3-gallate 
(EGCG) (Fig. 4a). These are two of the most active compounds in counteracting amyloidogenesis in a number 
of proteins involved in human disease10. An issue of concern in any sensor system is the possibility of having 
false positive results. To check if this were the case for WH1(R2-4)-RF1, the experiments with resveratrol and 
EGCG were repeated with the lacZ-WT reporter (Fig. 4b). Both the visual inspection of the liquid bacterial cul-
tures (Fig. 4b, top) and β-galactosidase assays with the WH1(R3)-RF1 chimera (Fig. 4b, bottom) indicated that 
while resveratrol, compared to its carrier solvent DMSO, had some enhancing effect of the enzymatic activity 
of β-galactosidase, EGCG significantly inhibited the reporter. In addition, serial culture dilutions on agar plates 
showed that EGCG had some inhibitory effect on bacteria growth, because it led to a smaller size of colonies, 
while resveratrol did not have such effect (Fig. 4c). Therefore, the reporter system based on the WH1(R2-4)-RF1 
and lacZ-amber is robust enough to screen for inhibitors of protein amyloidosis, provided that appropriate con-
trol assays on the compounds selected in the screening were performed. This must be also the case for any other 
reporter gene of choice (e.g., encoding luciferase or fluorescent proteins).
The effect of resveratrol on the WH1(R2-4)-RF1 chimeras was further characterized with the lacZ-amber 
reporter in liquid cultures in vivo (Fig. 5a). In β-galactosidase assays (Fig. 5a, bottom), as expected for a solubiliz-
ing effect of this polyphenol on the three chimeras, the levels of enzymatic activity, normalized to those measured 
for the untreated cells, decreased up to 50%, indicating a net increase in successful translation termination elicited 
by WH1(R2-4)-RF1. In parallel, we checked that resveratrol did not show any significant effect on the growth of 
bacteria (Fig. 5b).
Figure 3. At least two WH1(Rn) repeats fused to RF1 are required to enable stop codon read-through. (a) 
Serial dilutions of bacterial cultures on LB-agar expressing the reporters lacZ-WT (top) or lacZ-amber (bottom), 
a variant carrying a premature stop codon, in the presence of a chromogenic substrate (X-Gal). Aggregation of 
the WH1(R2-4)-RF1 chimeras at 42 °C promotes amber codon read-through, while the chimeras that remain 
soluble, WH1(R0-1)-RF1, efficiently promote the end of translation. (b) A liquid culture assay in supplemented 
minimal medium. Again, blue colour (stop codon read-through) is observed for the WH1(R2-4)-RF1 chimeras 
in the lacZ-amber background. (c) β-galactosidase activity was determined in cells expressing the WH1(R0-
4)-RF1 chimeras. Values show the percentage of activity for each chimera in combination with the lacZ-amber 
reporter, relative to the lacZ-WT reporter (inset). The histograms display the media and SDs (whiskers) from 4 
independent replicas.
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To determine if the reduced stop codon read-through indeed was a consequence of decreased aggregation 
of the RF1 chimeras due to the action of the polyphenol, the effect of resveratrol on the WH1(R3)-RF1 chi-
mera, which efficiently promoted amber stop codon read-through (Figs 3 and 4), was tested by semi-denaturing 
detergent agarose gel electrophoresis (SDD-AGE) (Fig. 5c). This is a technique capable to resolve large polydis-
persed amyloid aggregates on the basis of their resistance to solubilization by SDS27. Cell extracts from bacteria 
expressing WH1(R3)-RF1 in the presence of DMSO contained the chimeric protein as several oligomeric species, 
ranging from low to high molecular weights. However, those incubated in the presence of resveratrol showed a 
marked decrease in the amount of the largest aggregates. These results demonstrated that the reduction in the 
stop codon read-through by the ribosomes, as reported by the sensor, is a direct consequence of the ability of 
resveratrol to prevent the aggregation of the RF1 chimeras.
Figure 4. Screening the anti-amyloidogenic activity of polyphenolic compounds on WH1(R0-4)-RF1.  
(a) A multi-well plate assay (see Fig. 3b) in which the reading-through stop codon activity (blue colour in the 
lacZ-amber background) of the WH1(R0-4)-RF1 chimeras was tested in the presence of the indicated natural 
polyphenols. Resveratrol was the most efficient compound in reverting the read-through phenotype, i.e., lack 
of colour. (b) Resveratrol and EGCG (100 µM) were assayed in plates (top) and in vitro (bottom) in the lacZ-
WT background, as a control for a possible effect of these compounds on β-galactosidase activity. EGCG, 
but not resveratrol, decreased the blue colouration (top), in a reaction not dependent on stop codon read-
through. β-galactosidase assays (bottom) confirmed that, when compared with the co-solvent (DMSO), EGCG 
significantly decreased the activity of the enzyme, an evidence for its direct inhibition by this polyphenol. On 
the contrary, resveratrol apparently enhanced β-galactosidase activity. Data come from 6 independent replicas. 
(c) To further characterize the two more efficient compounds, their effects on the viability of bacteria expressing 
WH1(R3)-RF1 were checked through serial dilutions on agar plates. While resveratrol (top) did not show any 
significant effect on bacterial growth, colony size was consistently smaller upon EGCG treatment (bottom) in 
the lacZ-amber and WT backgrounds, an indication for some detrimental effect on bacterial physiology.
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In parallel to the re-assignment of stop codons to code for non-natural amino acids28–30, this report shows 
that a translation termination factor (RF1) can also be engineered in bacteria to survey the propensity to amy-
loid aggregation of a given protein sequence. Moreover, we show here that amyloid-tagged RF1 is amenable for 
testing in bacteria compounds targeting intracellular amyloidosis. Future developments will imply to test chi-
meras of RF1 with peptide sequences involved in human amyloidoses and to explore the robustness of the assay 
in large-scale screenings. Once these issues have been addressed, the amyloidogenic RF1 chimeras, due to the 
handiness and simplicity of bacteria, may be included as a first in vivo screening assay in drug discovery programs 
targeting amyloid proteinopathies.
Methods
Construction of the WH1(R0-4)-RF1 chimeras. The prfA gene, encoding the bacterial translation termi-
nation factor RF1, was amplified by PCR from pELI0226. Besides a SacII site, which is necessary to clone the prfA 
gene, SmaI and PvuI targets were included at the 5′ end of the forward primer for the subsequent introduction of 
tandem repeats of the RepA-WH1(A31V) amyloidogenic peptide (L26VLCAVSLI34)22,25 (Fig. 2a). The amplified 
prfA was cloned into pRG-SD1, a vector carrying a suboptimal translation initiation sequence (to assure low 
intracellular levels of the cloned chimeras) and expressing hexahistidine fusion proteins under the control of 
Figure 5. Resveratrol enhances solubility of the WH1(R2-4)-RF1 chimeras. (a) With a lacZ-amber reporter, 
resveratrol (100 µM) led to the loss of blue colour in the culture (top). β-galactosidase activity, normalized 
to that in DMSO, decreased in 40–60% for the chimeras (bottom; data from 6 independent assays). Both are 
indications of enhanced translation termination by ribosomes at the premature stop codon in the reporter. (b) 
At the concentration used in the assays (100 µM), resveratrol has no effect on the growth of E. coli cells at either 
of the temperatures used in the assays. (c) The effect of resveratrol on the aggregation of WH1(R3)-RF1 in vivo 
was assessed by SDD-AGE (left): the polyphenol (1 mM), but not its solvent (DMSO), reduced the population 
of high (HMW) molecular weight oligomers of the chimera, as expected from the solubilizing action of this 
polyphenol on amyloid aggregates10. As a control, 1 mM resveratrol does not have a detrimental effect on 
bacterial growth in the colour-based assay (right).
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an IPTG-inducible Ptac promoter31. The parental construction including prfA and none of the WH1 repeats was 
named pRG-WH1(R0)-RF1. Starting from this plasmid, the Ptac-His6-WH1(R0)-RF1 module was transferred 
to a plasmid with a low copy-number RK2 replicon18, to get pRK2-WH1(R0)-RF1. For the construction of the 
rest of the chimeras, the inserts with the tandem repeats of the amyloidogenic peptide were obtained by means 
of enzymatic digestion (SmaI and EcoRV) of the pUKC1620_R1-4 plasmids22. Fragments were then ligated with 
pRG-WH1(R0)-RF1, previously digested with SmaI, to build pRG-WH1(R1-4)-RF1. Finally, the inserts contain-
ing the R1-4, repeats fused to prfA were transferred (SmaI and BamHI digestion) to pRK2-WH1(R0)-RF1, thus 
generating the pRK2-WH1(R1-4)-RF1 vector series.
Construction of the pFus-lacZ-WT/amber vectors. The lacZ gene was amplified from pMLM13232 
using oligonucleotides with SpeI (forward) and SmaI (reverse) 5′ ends. Both the PCR product and the pFus 
vector33 were digested with those enzymes and then fragments were ligated to give the pFus-lacZ-WT plasmid, 
which carried the lacZ gene under the control of the arabinose-inducible ParaBAD promoter. The pFus-lacZ-amber 
plasmid (Fig. 2b) was generated by means of site-directed mutagenesis using Pfu Turbo (Stratagene) and specific 
oligonucleotides to introduce a premature amber termination codon (UAG) at the position 1545–1547 of lacZ 
(LacZ residue change: A515*)34.
Construction of the MRA8-∆lacZ strain. MRA8, an E. coli K-12 strain thermosensitive for RF1 due to 
the R137P mutation in the prfA gene35, was selected as host strain. The choice of a prfAts rather than a null strain, 
was imposed by the fact that prfA/RF1 is essential in E. coli36. MRA8 was transformed with pKD46, a plasmid 
expressing the λ-red recombinase under the control of the ParaBAD promoter37. Upon expression of λ-red (0.2% 
arabinose), 2 ml cultures were grown for 2 h at 30 °C and 1,100 rpm (Thermo Mixer Compact, Eppendorf). Cells 
were harvested and prepared in sterile H2O/glycerol for electroporation (MicroPulser, BioRad) with a PCR prod-
uct including a Km-parE cassette flanked by 50 bp from the 5′ an 3′ ends of lacZ, to get the MRA8 ∆lacZ::Km-parE 
strain. Using this strain as template, two 500-bp lacZ flanking regions were separately amplified by means of PCR. 
Both were ligated and then amplified, to generate a 1 kbp fragment that was used in a second recombination step 
in MRA8 ∆lacZ::Km-parE, as described above. To select for the recombinant cells, platting was performed on M9 
agar supplemented with 0.5% rhamnose, which induces the parE toxin38: only those cells having lost the Km-parE 
insert would grow under those conditions, giving place to the MRA8 ∆lacZ strain. All constructs were sequenced 
(Secugen Inc., CIB-CSIC).
Premature termination/read-through stop codon assays. All the assays were performed by express-
ing the WH1(R0-4)-RF1 chimeras in E. coli MRA8-∆lacZ cells, in such a way that genome-encoded RF1 is soluble 
and functional at 30 °C, but not at 42 °C. Cultures were grown in LB, or minimal medium plus casaminoacids 
(M9 + CAA), supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin, overnight at 30 °C. On the fol-
lowing day, they were inoculated (1/100) into fresh medium and allowed to grow at 30 °C until they reached an 
OD600nm of 0.3.
For the assays performed on agar plates. Serial dilutions of cultures were prepared (10−1–10−5). Subsequently, 
7 µl drops of each dilution were added to LB plates with 100 µg/ml ampicillin, 50 µg/ml kanamycin, 0.02 mM 
IPTG, 0.001% arabinose, 0.003% glucose and 40 µg/ml X-Gal. Then bacteria were grown at 30 °C or 42 °C over-
night to evaluate the read-through capacity of each chimera (i.e., colonies with a blue colouration).
For the assays performed in liquid. M9 + CAA, a colourless medium, was used. Five hundred µl of each cul-
ture (OD600nm = 0.3) were added to a p24 multi-well plate (Falcon). Each well was supplemented with 0.02 mM 
IPTG, 0.001% arabinose, 0.003% glucose and 40 µg/ml X-Gal, and the plates were grown at 42 °C and 300 rpm 
(Thermo Mixer Compact, Eppendorf) for 24 h. The same protocol was used in the case of the assays with inhib-
itors of amyloid aggregation (Sigma; 25 mM stocks in DMSO): 50 µM curcumin, 100 µM quercetin, 100 µM 
epigallocatechin-3-gallate (EGCG), 100 µM resveratrol and 37.5 µM myricetin.
β-galactosidase assays. Cultures at OD600nm = 0.3 were distributed into eight aliquots and the expression of 
β-galactosidase (LacZ) and the RF1 chimeras was simultaneously induced with 0.001% arabinose (plus 0.003% 
glucose) and 0.02 mM IPTG, respectively. Half of the samples were further grown at 30 °C and the other half at 
42 °C. LacZ activity was evaluated in cell extracts by a colorimetric assay: the degradation of ONPG39. At least 
3 independent experiments were performed for each chimera. For the assays performed in LB and with the 
lacZ-WT reporter, 200 µl culture aliquots were diluted to a final volume of 1 ml with Z buffer39, supplemented with 
50 µl 0.1% SDS and 100 µl chloroform, and incubated at 28 °C for 10 min. Then ONPG (Sigma) was supplemented 
to 4 µg/ml and the reaction was left to proceed for 5 min, when it was stopped with 500 µl 1 M Na2CO3. For the 
chimeras combined with the lacZ-amber reporter, cells from 8 ml of culture were processed and the reaction was 
carried out for 15 min. In the case of the assays in M9 + CAA medium, 200 µl of cultures and a reaction time of 
5 min were selected for lacZ-WT, whereas 300 µl and 15 min were used with the lacZ-amber reporter. With cells 
recovered from multi-well plates, the assay was performed at 24 h post-induction. β-galactosidase activity was 
quantitated according to the following formula39:
= × − . × × ×Miller units 1000 {[A (1 75 A )]/[t(min) V(ml) OD ]}420 550 600
where A420 is the absorption of the ONPG degradation products; (1.75 × A550) a light scattering correction factor 
at 420 nm; and OD600, a correction for the number of cells.
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Testing the aggregation of the WH1(R3)-RF1 chimera: SDD-AGE. The presence of SDS-resistant 
amyloid oligomers, an indication for protein amyloidogenesis, was evaluated by means of semi-denaturing 
detergent agarose gel electrophoresis (SDD-AGE), as described18,19. Bacteria were grown at 30 °C to OD600 = 0.3, 
when they were supplemented with 1 mM IPTG and resveratrol (1 mM), or its solvent (DMSO) as a control, 
and then transferred to 42 °C for 3 h. The high concentrations of both the inducer and the polyphenol, com-
pared with those used in the reporter β-galactosidase assays (see above), were due to the intrinsically limited 
sensitivity of SDD-AGE and, consequently, to the need of assuring sufficient intracellular amounts of the aggre-
gates and their titration by resveratrol. Then harvested bacteria were mechanically lysed using a Fast-Prep (MP 
Biomedicals; 1.0 mm Ø Lysing Matrix C). Thirty µl of the bacterial cell lysates were resolved by electrophoresis 
in a 1.5% agarose-TAE gel supplemented with 0.1% SDS. Gels were then blotted to a PVDF membrane by wet 
electro-transfer (Mini Trans-blot, BioRad). Anti-His monoclonal (1/500) and anti-mouse polyclonal (1/5,000) 
antibodies (Sigma) were used in sequential incubations. Detection was performed with the ECL Plus lumines-
cence kit (GE Healthcare) and AGFA Curix RP2 films.
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